Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Histamine dihydrochloride injection - Immune Pharmaceuticals

Drug Profile

Histamine dihydrochloride injection - Immune Pharmaceuticals

Alternative Names: Ceplene; Maxamine

Latest Information Update: 04 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EpiCept Corporation
  • Developer EpiCept Corporation; Immune Pharmaceuticals Inc; Karolinska University Hospital; MegaPharm Ltd; Nordic Group; Sahlgrenska University Hospital
  • Class Antineoplastics; Antivirals; Imidazoles; Small molecules
  • Mechanism of Action CYBB protein inhibitors; Immunomodulators; NADPH oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase I/II Chronic myelomonocytic leukaemia
  • Preclinical Solid tumours
  • Discontinued Alcoholic hepatitis; Hepatitis C; Malignant melanoma; Non-alcoholic steatohepatitis

Most Recent Events

  • 27 Nov 2018 Immune Pharmaceuticals and Vector Therapeutics plans to launch histamine dihydrochloride injection in Europe in 2019
  • 27 Nov 2018 Immune Pharmaceuticals and Vector Therapeutics enters into an option to acquire agreement for worldwide rights to Histamine dihydrochloride injection
  • 27 Nov 2018 Immune Pharmaceuticals and Vector Therapeutics plans to file regulatory applications for Acute myeloid leukemia in USA, China and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top